CMS finalizes Part B reimbursement rule

On Wednesday, CMS finalized a proposed rule whereby it will start to reimburse for certain Medicare drugs at 340B prices in January.

Under the new rule, CMS will reimburse hospitals that receive infused Medicare Part B drugs through the 340B program at a rate of average sales price (ASP) minus 22.5% instead of the current rate of ASP plus 6%. CMS Administrator Seema Verma said in a statement announcing the final rule that it would save patients an estimated $320 million on co-payments for drugs in 2018. ...